SCHEMBL2123865

SCHEMBL2123865

COc1cc(-c2nc3c(C#N)c[nH]n3c2Nc2cccc(C(F)(F)F)c2)cc(OC)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 3/20 0.50
▸ MAPT P10636 5/20 0.47
▸ EGFR P00533 1/20 0.46
▸ ERBB2 P04626 1/20 0.46
▸ TP53 P04637 1/20 0.43
▸ TEAD1 P28347 1/20 0.42
▸ TEAD4 Q15561 1/20 0.42
▸ TEAD2 Q15562 1/20 0.42
▸ ADORA2A P29274 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ GAA P10253 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ LMNA P02545 3/20 0.40
▸ HPGD P15428 2/20 0.40
▸ ABCG2 Q9UNQ0 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ PTK2 Q05397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2872219 0.87 MAPT (0.49) KDM5AMAPTEGFRERBB2TP53
SCHEMBL2122308 0.86 KDM5A (0.55) KDM5AMAPTTP53
SCHEMBL2126838 0.85 MAPT (0.47) KDM5AMAPTEGFRERBB2TP53
SCHEMBL2866440 0.84 KDM5A (0.54) KDM5AMAPTTP53
SCHEMBL2122450 0.84 KDM5A (0.51) KDM5AMAPTTP53GAASMN1; SMN2
SCHEMBL2126696 0.83 MAPT (0.54) KDM5AMAPTEGFRERBB2TP53
SCHEMBL2873308 0.83 KDM5A (0.51) KDM5AMAPTEGFRERBB2TP53
SCHEMBL2123358 0.81 KDM5A (0.50) KDM5AMAPTEGFRERBB2TP53
SCHEMBL2125620 0.79 KDM5A (0.48) KDM5AMAPTEGFRERBB2TP53
SCHEMBL2125958 0.79 KDM5A (0.48) KDM5AMAPTEGFRERBB2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KDM5A 1592/4885MAPT 4045/4885EGFR 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback